Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nutt

Showing results (331-340 of 789) with videos related to

Pageof 79
Sort By:
The Lancet. Psychiatry|September 12, 2015
Attacks on antidepressants: signs of deep-seated stigma?David J Nutt, Guy M Goodwin, Dinesh Bhugra, et al.
European Journal of Pharmacology|April 22, 1983
Hypophysectomy alters both 5-hydroxytryptamine- and alpha 2-adrenoceptor-mediated behavioural changes in the ratD J Heal, K M O'Shaughnessy, S L Smith, et al.
Journal of Psychopharmacology (Oxford, England)|June 23, 2016
Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocationS D Hood, C J Bell, S V Argyropoulos, et al.
European Journal of Pharmacology|January 8, 1985
The benzodiazepine antagonist, Ro 15-1788 does not decrease ethanol withdrawal convulsions in ratsH J Little, S C Taylor, D J Nutt, et al.
Addiction Biology|May 15, 2003
Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge testJ K Melichar, J S Myles, C B Eap, et al.
British Journal of Pharmacology|June 1, 1992
The effects of idazoxan and other alpha 2-adrenoceptor antagonists on urine output in the ratH C Jackson, I J Griffin, S D Birkett, et al.
Journal of Psychopharmacology (Oxford, England)|October 14, 2011
Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)Jayne E Bailey, Gerard R Dawson, Colin T Dourish, et al.
BMJ (Clinical Research Ed.)|April 17, 2004
Treatment of anxiety and depressive disorders in patients with cardiovascular diseaseSimon J C Davies, Peter R Jackson, John Potokar, et al.
Journal of Psychopharmacology (Oxford, England)|June 21, 2013
Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disordersR L Carhart-Harris, S Brugger, D J Nutt, et al.
Nature Reviews. Neuroscience|April 16, 2015
The dopamine theory of addiction: 40 years of highs and lowsDavid J Nutt, Anne Lingford-Hughes, David Erritzoe, et al.
Pageof 79

Showing results (331-340 of 789) with videos related to

Sort By:
Pageof 79
The Lancet. Psychiatry|September 12, 2015
Attacks on antidepressants: signs of deep-seated stigma?David J Nutt, Guy M Goodwin, Dinesh Bhugra, et al.
European Journal of Pharmacology|April 22, 1983
Hypophysectomy alters both 5-hydroxytryptamine- and alpha 2-adrenoceptor-mediated behavioural changes in the ratD J Heal, K M O'Shaughnessy, S L Smith, et al.
Journal of Psychopharmacology (Oxford, England)|June 23, 2016
Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocationS D Hood, C J Bell, S V Argyropoulos, et al.
European Journal of Pharmacology|January 8, 1985
The benzodiazepine antagonist, Ro 15-1788 does not decrease ethanol withdrawal convulsions in ratsH J Little, S C Taylor, D J Nutt, et al.
Addiction Biology|May 15, 2003
Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge testJ K Melichar, J S Myles, C B Eap, et al.
British Journal of Pharmacology|June 1, 1992
The effects of idazoxan and other alpha 2-adrenoceptor antagonists on urine output in the ratH C Jackson, I J Griffin, S D Birkett, et al.
Journal of Psychopharmacology (Oxford, England)|October 14, 2011
Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)Jayne E Bailey, Gerard R Dawson, Colin T Dourish, et al.
BMJ (Clinical Research Ed.)|April 17, 2004
Treatment of anxiety and depressive disorders in patients with cardiovascular diseaseSimon J C Davies, Peter R Jackson, John Potokar, et al.
Journal of Psychopharmacology (Oxford, England)|June 21, 2013
Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disordersR L Carhart-Harris, S Brugger, D J Nutt, et al.
Nature Reviews. Neuroscience|April 16, 2015
The dopamine theory of addiction: 40 years of highs and lowsDavid J Nutt, Anne Lingford-Hughes, David Erritzoe, et al.
Pageof 79